International expert consensus on the management of bleeding during VATS lung surgery
Lunxu Liu(Sichuan University), Alessandro Brunelli(St James's University Hospital), Jiandong Mei(Sun Yat-sen University), Yuming Zhu(Third People 's Hospital of Chongqing), Jian Hu(National Medical Products Administration), Gening Jiang(Tongji University), Xingyi Zhang(Anhui University), Luca Bertolaccini(University of Milan), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Serdar Evman(Chest Diseases Hospital), Wentao Fang(Shanghai Jiao Tong University), Shidong Xu(Harbin Medical University), Yi‐Dan Lin(Sichuan University), Todd L. Demmy(Roswell Park Comprehensive Cancer Center), Deruo Liu(Roswell Park Comprehensive Cancer Center), Gregor J. Kocher(Roswell Park Comprehensive Cancer Center), Xiangning Fu(Tongji University), Qinghua Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Ti Tong(Roswell Park Comprehensive Cancer Center), Javier Aragón(Roswell Park Comprehensive Cancer Center), Qiang Pu(Sichuan University), Liang Chen(Nanjing Brain Hospital), Qun Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaofei Li(Air Force Medical University), Chun Chen(Sun Yat-sen University), Zhu Zhang(Sichuan University), Xun Zhang(Zaozhuang University), Yin Li(Third Affiliated Hospital of Sun Yat-sen University), Lin Ma(Sichuan University), Jie He(First Affiliated Hospital of Jinan University), Lin Xu(Guangdong Pharmaceutical University), Shanqing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianhua Fu(Bristol-Myers Squibb (Germany)), Hui Li(Tianjin University), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Tiansheng Yan(Beijing University of Chinese Medicine), Zhentao Yu(Bristol-Myers Squibb (Germany)), Yunchao Huang(Kunming Medical University), Lanjun Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lijie Tan(Fudan University), Qunyou Tan(Sichuan University), Weimin Mao(Bristol-Myers Squibb (Germany)), Zhongmin Jiang(Chinese People's Liberation Army), Yongyu Liu(Sun Yat-sen University), Yang Liu(China National GeneBank), Qingquan Luo(Shanghai Jiao Tong University), Haiquan Chen(Shanghai Jiao Tong University), Guowei Che(Sun Yat-sen University)
Cited by 42
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
|Nature Medicine|2018|1.8k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k